What dose of Uzedy (risperidone) is equivalent to a daily oral dose of 2 mg risperidone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Uzedy Dose Equivalent to 2mg Oral Risperidone

For a patient taking 2mg of oral risperidone daily, the equivalent Uzedy dose is 50mg once monthly or 100mg once every 2 months. 1

Dosing Conversion

According to the FDA-approved prescribing information for Uzedy, the conversion from oral risperidone to this long-acting subcutaneous formulation follows a straightforward table 1:

  • 2mg oral risperidone daily = 50mg Uzedy once monthly OR 100mg Uzedy once every 2 months

Key Administration Details

Uzedy must be administered by a healthcare professional as a subcutaneous injection in either the abdomen or upper arm 1. The first Uzedy injection should be given the day after the last dose of oral risperidone, with no loading dose or supplemental oral risperidone required 1.

Important Considerations:

  • Tolerability must be established first: Patients who have never taken risperidone should establish tolerability with oral risperidone before initiating Uzedy 1

  • Flexible dosing schedules: Patients can switch between monthly and every-2-month dosing regimens by administering the first dose of the new schedule on the next scheduled date 1

  • Special populations: For patients with renal or hepatic impairment, titrate with oral risperidone to at least 2mg once daily first, then the recommended Uzedy dose is 50mg once monthly 1

Clinical Context

The conversion factor represents approximately a 25-fold difference between oral risperidone and Uzedy doses 2. This reflects the pharmacokinetic differences between immediate-release oral formulations and the extended-release subcutaneous depot formulation, which provides sustained drug release over the dosing interval with less peak-to-trough fluctuation 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.